Els A Goulmy

Title: The Innovative Contributions of Els A Goulmy

Introduction

Els A Goulmy is a prominent inventor based in Oegstgeest, Netherlands. She has made significant contributions to the field of immunology, particularly in the context of transplantation and cancer treatment. Her work focuses on the development of peptides that play a crucial role in addressing Graft-versus-Host Disease.

Latest Patents

Els A Goulmy holds a patent for the HA-2 antigenic peptide. This invention discloses the first peptide sequence of a minor H antigen, which is associated with Graft-versus-Host Disease. The peptide and its derivatives have numerous applications in bone marrow transplantation, organ transplantation, and the treatment of leukemia. The peptide is derived from the HA-2 minor antigen and has the sequence YXGEVXVSV (SEQ ID NO: 1), where X represents a leucine or an isoleucine residue. Both donors and recipients in bone marrow transplantation can benefit from treatment with these peptides, which can be combined with other peptides, carriers, suitable excipients, and adjuvants.

Career Highlights

Els A Goulmy is affiliated with Leiden University, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of minor H antigens and their implications in transplantation medicine.

Collaborations

Els has collaborated with notable colleagues, including Donald F Hunt and Victor H Engelhard, to further her research initiatives and enhance the impact of her inventions.

Conclusion

Els A Goulmy's innovative work in the field of immunology, particularly with her HA-2 antigenic peptide, showcases her dedication to improving medical treatments for patients undergoing transplantation. Her contributions are vital in the ongoing fight against Graft-versus-Host Disease and related conditions.